QUOTE AND NEWS
Benzinga  2 hrs ago  Comment 
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced Ronald C. Renaud, Jr. has been appointed to Chimerix's Board of Directors. Mr. Renaud currently...
FierceBiotech  Dec 1  Comment 
Just a few months after Ron Renaud completed the sale of Idenix to Merck for $3.85 billion, the biotech CEO's vacation is officially over. Instead, he's opening a new chapter in his career--taking the helm at the upstart RaNA in Cambridge, MA, and...
FiercePharma  Oct 28  Comment 
Novartis' third-quarter profit may have gotten a large boost from the sale of its Idenix stake to Merck this summer, with cost cuts kicking in, too. But when it comes to top-line results that topped analysts' forecasts, the company has its own hot...
SeekingAlpha  Sep 3  Comment 
By Jim Fink: Here's an important trend in the investment world right now: the recent buyouts of small-cap biotech companies like Idenix (NASDAQ: IDIX) and Intermune (NASDAQ: ITMN). Why so many pharma deals? Merck (NYSE:MRK), one of the largest...
SeekingAlpha  Aug 26  Comment 
By Matthew Finston: Klarman Did What?? Hedge fund manager, Seth Klarman, recently took a 14.06% stake in Veritiv Corp (NYSE:VRTV) for his fund Baupost. Klarman is notorious for bringing an average annual return of 19% for his fund and doing...
SeekingAlpha  Aug 15  Comment 
By John Vincent: This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's U.S. stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/14/2014. Please visit our...
SeekingAlpha  Aug 6  Comment 
ByPrescient Investment Analysis: Gilead Sciences (NASDAQ:GILD) is one of the more compelling companies on the market. Anyone who is familiar with the company is aware that Sovaldi is hailed as a cure for hepatitis C, and prevents the need for...
newratings.com  Aug 5  Comment 
WHITEHOUSE STATION (dpa-AFX) - Healthcare giant Merck & Co. Inc. (MRK) Tuesday announced the successful completion of the tender offer for all shares of Idenix Pharmaceuticals, Inc. (IDIX) at a purchase price of $24.50 per share. As of the tender...
SeekingAlpha  Aug 4  Comment 
Here's the list of our Outstanding Performance Award Winners to date. We will be updating weekly: Winners on July 28, 2014 Unconventional Capital Wisdom - Long IDIX (Idenix Pharmaceuticals), July 30, Complete Story ยป
SeekingAlpha  Jul 28  Comment 
Congratulations to our first two Outstanding Performance award winners: Winner #1: IDIX (Idenix Pharmaceuticals) by Unconventional Capital Wisdom, July 30, 2013. +597% Winner #2: FNHC (Federated National Holdings Company) by Nitor Capital,...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki